Business
Latigo Raises $345.6M in Upsized IPO for Non-Opioid Pain
Latigo Biotherapeutics raised $345.6 million in an upsized initial public offering, pricing at the top end of a marketed range and issuing 19.2 million…
Latigo Biotherapeutics raised $345.6 million in an upsized initial public offering, pricing at the top end of a marketed range and issuing 19.2 million…
Latigo Biotherapeutics has filed for an initial public offering, joining biotech firms considering public markets as early as this quarter. Latigo focuses on non-opioid…